An increasing number of patients with metastatic colorectal cancer (mCRC) are able to
receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and
panitumumab is the main targeted treatment to combine with standard chemotherapy for …

3535 Background: Cetuximab (Erbitux), an IgG1 monoclonal antibody that specifically
targets EGFR the receptor, is effective in combination with irinotecan or irinotecan/5-FU/FA …

Metastatic colorectal cancer (mCRC) remains incurable in most cases, but survival has
improved with advances in cytotoxic chemotherapy and targeted agents. However, the …

LBA3506 The full, final text of this abstract will be available at abstract. asco. org at 7: 30 AM
(EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online …

Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion
(PCO), offers timely clinical direction to ASCO's oncologists following publication or …

PURPOSE To verify whether the intensification of the upfront chemotherapy backbone with a
modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan …

Purpose The occurrence of KRAS mutation is predictive of nonresponse and shorter survival
in patients treated by anti–epidermal growth factor receptor (anti-EGFR) antibody for …

Survival of patients with metastatic CRC (mCRC) has improved steadily over the past
several decades, due largely to the development of new combinations of standard …